Table 1 Ferroptosis inducers that work against CRPC.

From: Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies

Classification

Compound

Target

Cell line

Mechanism

Class I

Erastin

SLC7A11

DU145, PC3, 22Rv1, LNCaP, NCI-H660, ARCaP, C4-2, and LNCaP

Inhibit SLC7A11 activity

AR and SLC7A11

22Rv1, LNCaP95

Reduction of the expression and transcriptional activity of AR, AR-V7 and GPX4

Buthionine Sulphoximine (BSO)

GSH

VCaP, 22Rv1

Inhibit GSH synthesis

Class II

RSL3

GPX4

LNCaP, 22RV1, C4-2B, DuCaP

Inhibit GPX4 activity

Class III

FIN56

CoQ, GPX4

LNCaP, VCaP, 22Rv1

Deplete CoQ and degrade GPX4